Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Expensify Inc (EXFY) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance

Expensify IncTrade
SELLAS Life Sciences Group Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Expensify Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Expensify Inc trades at $2.37 (market cap $208.82M), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.4 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 10.9× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, SELLAS Life Sciences Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals.

EXFYSLS
Market Cap
$208.82M$2.27B
Volume
456,1024,179,659
Sector
TechnologyHealth
52-Week High
$2.72$15.46
52-Week Low
$0.75$1.39
Typical Hold Time
41 Days—
Enterprise Value
$148.44M$2.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Expensify Inc

Expensify (EXFY) trades at $2.37, up 4.41% with a neutral technical signal despite bullish moving averages. The company shows mixed fundamentals with a high P/E ratio of 258.82 but improving cash flow trends, with Q2 2026 earnings beating expectations. Recent news highlights strategic integrations with AI-native ERP platforms and European expansion of its corporate card offering, signaling growth initiatives.

The outlook remains speculative with analyst consensus bullish (50% buy ratings) and a $13.75 price target, but negative net income margins and competitive pressures pose risks. Investment opportunity hinges on successful execution of AI-driven products and international growth, while downside risks include sustained profitability challenges and market volatility.

SELLAS Life Sciences Group Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EXFY
0% Buy100% Sell
Avg holding period · 41 Days
SLS

No sentiment data available yet.

About Expensify Inc

Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.

Read more on EXFY →

About SELLAS Life Sciences Group Inc. Common Stock

SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.

Read more on SLS →